The goal of this clinical trial is to learn about IMM60 with or without pembrolizumab in
participants with advanced melanoma or non-small cell lung cancer. There are two phases:
- Phase 1: This phase is designed to learn about the safety of IMM60 with or without
pembrolizumab and to find a safe dose to test in Phase 2.
- Phase 2: This phase is designed to learn whether IMM60 + pembrolizumab improves
progression-free survival at 12 months compared to pembrolizumab alone in participants
with non-small cell lung cancer.